Shares of Scholar Rock Holding (NASDAQ: SRRK) are soaring today, up 13.7% as of 1:14 p.m. ET. The move comes as the S&P 500 and Nasdaq Composite were up modestly.
Scholar Rock, a biopharma company, reported positive results from a phase 2 trial of its muscle-preserving weight-loss therapy.
The study evaluated Scholar Rock’s apitegromab in combination with Eli Lilly‘s blockbuster weight-loss drug tirzepatide (sold as Mounjaro and Zepbound). The combo showed a significant reduction in lean mass loss, a major issue with current GLP-1 treatments.